Laura Sepp-Lorenzino, Ph.D., is executive vice president, chief scientific officer of Intellia Therapeutics, Inc. Prior to joining Intellia in May 2019, she was vice president, head of nucleic acid therapies, member of the research leadership and external innovation at Vertex Pharmaceuticals, Inc. from September 2017 to May 2019. From April 2014 to September 2017, Dr. Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the hepatic infectious disease strategic therapeutic area at Alnylam Pharmaceuticals, Inc., and was at Merck from 1999 to 2014, most recently as Executive Director in RNA Therapeutics. Laura is a member of the scientific advisory boards of Thermo Fisher Scientific, Lodo Therapeutics, and the U.K. Medical Research Council Nucleic Acid Therapy Accelerator. In December 2020 she joined the board of directors of Taysha Gene Therapies, a biopharmaceutical company focused on developing treatments for monogenic diseases in the central nervous system. Dr. Sepp-Lorenzino is also a member of the board of directors of the Oligonucleotide Therapeutics Society. Dr. Sepp-Lorenzino earned a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and a Ph.D. in biochemistry from New York University.
Laura Sepp-Lorenzino, PhD
Chief Scientific Officer, Executive Vice President, Intellia Therapeutics